Compliance Architects® is Gold Sponsor of FDLI Enforcement, Litigation & Compliance Conference 2013
Compliance Architects
Compliance Architects® is proud to announce that it will be a Gold Sponsor of the upcoming FDLI Enforcement, Litigation & Compliance Conference to be held in Washington, DC on December 10 & 11, 2013. The Food and Drug Law Institute (FDLI) is the country’s premiere organization dedicated to the legal and regulatory challenges faced by companies regulated by the US Food and Drug Administration.
The following is a description of the conference from the FDLI conference website:
Whether you are a regulator, litigator, compliance specialist or consultant, it is critical to keep up with the changing trends in enforcement, litigation, and compliance. Across all agency-regulated products, the Food and Drug Administration (FDA) is expected to continue its heightened enforcement efforts. The Department of Justice and States’ Attorney General offices are becoming increasingly active in securing Consent Decrees and Corporate Integrity Agreements. Public advocacy groups are voicing their concerns that compliance is a top priority. This two-day conference will thoroughly examine the changes in law, regulation and practice in the last year and predict changes in the year ahead. Attendees will hear from top regulatory agency officials, including Office of Compliance directors invited from all six product Centers at FDA, the Department of Justice, HHS Office of the Inspector General (OIG), industry and the private bar.
Compliance Architects
Compliance Architects® delivers compliance and quality consulting, outsourcing, staff augmentation, and technology-related services to companies directly regulated by the United States Food and Drug Administration (FDA). With service capabilities ranging from quality systems’ implementation to audits, outsourced compliance services, inspection readiness, and complex enforcement remediation, Compliance Architects® has the experience, expertise, and delivery capability that will result in significantly improved FDA compliance outcomes for any size organization.